Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 16, 2007 - Issue 10
Submit an article Journal homepage
74
Views
4
CrossRef citations to date
0
Altmetric
Perspective

Discontinued drugs in 2006: renal, endocrine and metabolic drugs

Jerry R Colca Metabolic Solutions Development Company, 125 S. Kalamazoo Mall #202, Kalamazoo, MI 49007, USA +1 269 267 3567; +1 616 940 6223; [email protected]
Pages 1517-1523 | Published online: 09 Oct 2007

Bibliography

  • YKI-JARVINEN H: Thiazolidinediones. N. Engl. J. Med. (2004) 351:1106-1118.
  • GEGICK CG, ALTHEIMER MD: Comparison of effects of thiazolidinediones on cardiovascular risk factors: observations from a clinical practice. Endocr. Pract. (2001) 7:162-169.
  • ERDMANN E, DORMANDY JA, CHARBONNEL B, MASSI-BENEDETTI M, MOULES IK, SKENE AM: The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with Type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) study. J. Am. Coll. Cardiol. (2007) 49(17):1772-1780.
  • NISSEN SE, WOLSKI K: Effects of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N. Engl. J. Med. (2007) 356(24):2457-2471.
  • OLEFSKY JM, SALTIEL AR: PPAR γ and the treatment of insulin resistance. Trends Endocrinol. Metab. (2000) 11:362-368.
  • POURCET B, FRUCHART JC, STAELS B, GLINEUR C: Selective PPAR modulators, dual and pan PPAR agonists: multimodal drugs for the treatment of Type 2 diabetes and atherosclerosis. Expert Opin. Emerg. Drugs (2006) 11(3):379-401.
  • DRUCKER DJ: Enhancing incretin action for the treatment of Type 2 diabetes. Diabetes Care (2003) 26:2929-2940.
  • AMORI E, LAU J, PITTAS AG: Efficacy and safety of incretin therapy in Type 2 diabetes: systematic review and meta-analysis. JAMA (2007) 298:194-206.
  • INUI A, ASAKAWA A, BOWERS CY et al.: Ghrelin, appetite, and gastric motility: the emerging role of the stomach as an endocrine organ. FASEB J. (2004) 18:439.
  • COLCA JR: Discontinued drugs in 2005: endocrine and metabolic. Expert Opin. Investig. Drugs (2007) 16(2):129-136.
  • HEGARTY BD, FURLER SM, OAKES ND, KRAEGEN EW, COONEY GJ: Peroxisome proliferator-activated receptor (PPAR) activation induces tissue-specific effects on fatty acid uptake and metabolism in vivo – a study using the novel PPAR/agonist tesaglitazar. Endocrinology (2004) 145:3158-3164.
  • OAKES ND, THALEN, HULSTRAND T et al.: Tesaglitazar, a dual PPAR/agonist, ameliorates glucose and lipid intolerance in obese Zucker rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. (2005) 289:R938-R946.
  • GOLDSTEIN BJ, ROSENSTOCK J, ANZALONE D, TOU C, OHMAN KP: Effect of tesaglitazar, a dual PPAR α/γ agonist, on glucose and lipid abnormalities in patients with Type 2 diabetes: a 12-week dose-ranging trial. Curr. Med. Res. Opin. (2006) 22(12):2575-2590.
  • FAGERBERG B, EDWARDS S, HALMOS J et al.: Tesaglitazar, a novel dual peroxisome proliferator-activated receptor α/γ agonist, dose-dependently improves the metabolic abnormalities associated with insulin resistance in a non-diabetic population. Diabetologia (2005) 48(9):1716-1725.
  • HELLMOLD H, ZHANG H, ANDERSSON U et al.: Tesaglitazar, a PPAR/agonist, induces interstitial mesenchymal cell DNA synthesis and fibrosarcomas in subcutaneous tissues in rats. Toxicol. Sci. J. (2007) 98:63-74.
  • HARRITY T, FARRELLY D, TIEMAN A et al.: Muraglitazar, a novel dual (/) peroxisome proliferator-activated receptor activator, improves diabetes and other metabolic abnormalities and preserves β-cell function in db/db mice. Diabetes (2006) 55:240-248.
  • KENDALL DM, RUBIN CJ, MOHIDEEN P et al.: Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (/) peroxisome proliferator-activated receptor activator, in patients with Type 2 diabetes inadequately controlled with metformin monotherapy: a double-blind, randomized, pioglitazone-comparative study. Diabetes Care (2006) 29:1016-1023.
  • BUSE JB, RUBIN CJ, FREDERICH R et al.: Muraglitazar, a dual (α/γ) PPAR activator: a randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with Type 2 diabetes. Clin. Ther. (2005) 27(8):1181-1195.
  • TANNEHILL-GREGG SH, SANDERSON TP, MINNEMA D et al.: Rodent carcinogenicity profile of the antidiabetic dual PPAR and agonist muraglitazar. Toxicol. Sci. (2007) 98:258-270.
  • NISSEN SE, WOLSKI K, TOPOL EJ: Effect of muraglitazar on death and major adverse cardiovascular events in patients with Type 2 diabetes mellitus. JAMA (2005) 294:2581-2586.
  • COLCA JR, KLETZIEN RF: What has prevented the expansion of insulin sensitisers? Expert Opin. Investig. Drugs (2006) 15(3):205-210.

Website

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.